TweetVery interesting
TweetOne dose of myostatin inhibitor bimagrumab results in permanent muscle mass increase
One dose of myostatin inhibitor bimagrumab results in permanent muscle mass increase
People with type-2 diabetes can build up a couple of kilos of muscle mass and lose a couple of kilos of fat, without training or changing their diet, by taking a one-time dose of the myostatin inhibitor bimagrumab. A study by researchers at Novartis has shown this to be the case.
Bimagrumab
Bimagrumab is also called BYM338. It is an antibody, developed by Novartis, which attaches itself to the activin type II receptor-A and activin type II receptor-B. This prevents muscle-growth inhibiting proteins such as myostatin, GDF-11 and activin from working, and as a result muscles grow bigger and stronger.
The pharmaceutical industry has been experimenting for years with myostatin inhibitors, and some of them are already marketed as 'research chemicals'. These grey market inhibitors are not particularly effective, however. Apart from a few substances, it is mostly the pharmaceutical industry rejects that athletes manage to get their hands on in this way.
One dose of myostatin inhibitor bimagrumab results in permanent muscle mass increase
Going by the promising human studies published, bimagrub is certainly not a reject. [J Cachexia Sarcopenia Muscle. 2017 Sep 14. doi: 10.1002/jcsm.12205. [Epub ahead of print].] [J Am Geriatr Soc. 2017 Jun 27. doi: 10.1111/jgs.14927. [Epub ahead of print].] [Neurology. 2014 Dec 9;83(24):2239-46.]
Study
The researchers gave 10 overweight people with type-2 diabetes 30 mg bimagrumab per kg bodyweight intravenously. A similar control group was given a placebo.
Results
In week 14 the lean body mass of the participants who had been given bimagrumab had increased by 5 percent since week 0, and their body fat had decreased by 10 percent.
The effects were still visible six months after the bimagrumab had been administered.
One dose of myostatin inhibitor bimagrumab results in permanent muscle mass increase
Myostatin
The insulin sensitivity and glucose balance of the participants who had received bimagrumab improved.
Side effects
"Acne, muscle spasms and myalgia were reported in 30% of bimagrumab-treated participants and in none of the placebo-treated participants; there were no changes in creatine kinase levels," wrote the researchers. "Diarrhoea, muscle weakness and musculoskeletal stiffness were noted in 10% of the bimagrumab group and in none of the placebo group."
"All events were described as minor and transient and resolved spontaneously by the end of the trial."
"Overall, bimagrumab was safe and well tolerated".
Conclusion
"Bimagrumab has potential to be developed for metabolic complications of obesity such as insulin resistance, although this was only an exploratory study," the researchers concluded.
"A trial with bimagrumab in addition to caloric restriction in obese patients with type-2 diabetes is ongoing, with the aim of evaluating the translatability of these pilot findings on body composition, body weight and metabolic variability." [clinicaltrials.gov]
"It is possible that bimagrumab could be a novel insulin-sensitizing therapeutic agent for type-2 diabetes through its meaningful effect on body composition. Unlike the available therapeutics for type-2 diabetes, which tend to increase weight and fat mass, bimagrumab could reverse important features of the underlying pathophysiology by having a positive effect on body composition in people with type-2 diabetes, and improve insulin sensitivity."
Source:
Diabetes Obes Metab. 2017 Jun 23. doi: 10.1111/dom.13042. [Epub ahead of print].
TweetVery interesting
TweetJoe have you ever tried anything similar?
Yk11?
Last edited by Uncle Ric; 12-13-2017 at 10:26 PM.
TweetNever.I have a Epicatechin product and it did nothing at all. Effects of (−)-epicatechin on molecular modulators of skeletal muscle growth and differentiation
I wish I can find a good source for YK11.
TweetHuman studies
In human subjects, with aging, SkM levels of myostatin and SA-β-Gal significantly increase (28%, 48%) while those of follistatin (30%), MyoD (41%) and myogenin (47%) decrease, changes largely in concert with mouse results (figure 2A-C). Treatment for 7 days with Epi yielded a bilateral increase in hand strength of ~7% which was accompanied by a significant increase (49.2 ± 16.6 %) in the ratio of plasma follistatin/myostatin levels (data not shown).
TweetThat is a great change if it really works
TweetI agree. I look forward to more studies
Tweetvery interesting indeed. don't think it would replace aas by any means with the side effects of muscle weakness and spasms but very good news on the obesity and diabetes front.
TweetI think it would be an awesome addition to an AAS cycle but i wouldnt do it stand alone. Im sure it would benefit all by itself but i'd want the best results possible. So yk11 is legit? I never really took much stock in the whole myostatin inhibitor hype.
"I don't need the promise of Heaven or the threat of HELL to be a good person"
TweetDoes anyone know a good place to find it
Tweeti wish they wouldnt do these trials with aging people. it screws up the percentages and results. dhea and daa work excellent in aging people but really dont do dick for younger people. so it does us no good when the research group are already significantly in decline to begin with
TGBSupplements REP
https://www.tgbsupplements.com/
Use code 'Baby1' for $5 off your order
Tweetyeah but that is where they will make $$$. helping elderly and ill folk maintain or build muscle mass.
TweetSarms Search has legit YK11.....Give them a try wwww.sarmssearch.com